Ipamorelin Dosage: Doses Studied, Units and Chart
What doses of Ipamorelin have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 8 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- 2 hours terminal half-life
- intravenous infusion (15 min), in people · Pharmaceutical research 1999, PMID 10496658
- Vial sizes sold
- 2 mg, 5 mg, 10 mg
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 0.03 mg/kg ipamorelin | twice daily · intravenous infusion · postoperative day 1 to 7 or hospital discharge | Human RCTn = 117 | International journal of colorectal disease 2014, PMID 25331030 |
| 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg | single · intravenous infusion over 15 minutes | Human RCT | Pharmaceutical research 1999, PMID 10496658 |
| 1-3 mg/kg | every 24 h · intraperitoneal · up to 72 h | Animal · ferret (not a human result) | Physiology & behavior 2024, PMID 39043357 |
| 0.014-0.14 umol/kg | single · intravenous | Animal · rat (not a human result) | Journal of experimental pharmacology 2012, PMID 27186127 |
| 0.01-1 mg/kg | single dose or four doses a day at 3-h intervals for 2 days · intravenous bolus · 48 h | Animal · rat (not a human result) | The Journal of pharmacology and experimental therapeutics 2009, PMID 19289567 |
| 100 microg/kg | three times daily · subcutaneous · 3 months | Animal · rat (not a human result) | Growth hormone & IGF research 2001, PMID 11735244 |
| 0.5 mg/kg per day | continuous · subcutaneous (osmotic minipump) · 12 weeks | Animal · rat (not a human result) | The Journal of endocrinology 2000, PMID 10828840 |
| 0, 18, 90 and 450 microg/day | three times daily · subcutaneous · 15 days | Animal · rat (not a human result) | Growth hormone & IGF research 1999, PMID 10373343 |
Dose to syringe units
For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 100 mcg
- 2 u
- 200 mcg
- 4 u
- 300 mcg
- 6 u
- 500 mcg
- 10 u
- 1000 mcg
- 20 u
Before anyone considers it
- Ipamorelin is not FDA approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
The human studies were intravenous
The postoperative ileus trial gave intravenous ipamorelin 0.03 mg/kg twice daily from postoperative day 1 to 7 or hospital discharge.[3]
Its authors reported that 0.03 mg/kg twice daily for up to 7 days was well tolerated and did not differ significantly from placebo on the key and secondary efficacy analyses.[3]
A pharmacokinetic study escalated across 5 infusion rates, from 4.21 to 140.45 nmol/kg over 15 minutes, with eight healthy men at each level.[4]
Rat studies used continuous and three-times-daily schedules
Adult female rats were injected subcutaneously three times daily for 15 days at 0, 18, 90 and 450 microg/day.[10]
In a 12-week rat study, ipamorelin 0.5 mg/kg per day was delivered continuously by subcutaneous minipump.[9]
Drugs@FDA lists no ipamorelin product, so no label anchors these human or animal figures.[11]
Common questions
How many units is 300 mcg of Ipamorelin?
It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 300 mcg is 6 units on a U-100 syringe. Use the calculator for other mixes.
Is Ipamorelin FDA approved?
No. Ipamorelin is not FDA approved for any use.
What is the ipamorelin dosage chart?
None can be sourced. Drugs@FDA lists no ipamorelin product, and the human trials on this page used intravenous infusion.[11]
Is there an ipamorelin dosing schedule in studies?
The one human treatment trial gave intravenous infusions twice daily for up to 7 days after bowel surgery.[3]
More on Ipamorelin
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 4Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 5The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
- 6Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.Journal of experimental pharmacology · 2012PMID 27186127Accessed 2 Oct 2026
- 7Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.The Journal of pharmacology and experimental therapeutics · 2009PMID 19289567Accessed 2 Oct 2026
- 8The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001PMID 11735244Accessed 2 Oct 2026
- 9The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.The Journal of endocrinology · 2000PMID 10828840Accessed 2 Oct 2026
- 10Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1999PMID 10373343Accessed 2 Oct 2026
- 11Drugs@FDA (openFDA) search: active ingredient "ipamorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.